Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EVH stock price vs NVST: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NVST's multiple
Needs Annual EPS, NVST P/E.
Implied fair value · at EVH's multiple
Needs Annual EPS, EVH P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Evolent Health, Inc. · implied price per share
Reporting currency could not be verified.
Envista Holdings Corp · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
EVH · not enough data.
NVST · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cigna Group
EVH vs CI
MOLINA HEALTHCARE, INC.
EVH vs MOH
Teladoc Health, Inc.
EVH vs TDOC
CLOVER HEALTH INVESTMENTS, CORP. /DE
EVH vs CLOV
UNITEDHEALTH GROUP INC
EVH vs UNH
ALIGN TECHNOLOGY INC
EVH vs ALGN
HENRY SCHEIN INC
EVH vs HSIC
PATTERSON COMPANIES, INC.
EVH vs PDCO
DENTSPLY SIRONA Inc.
EVH vs XRAY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EVH can stabilize revenue and convert its negative margins into sustained profitability, then EVH could be a value opportunity because its P/S multiple is only 0.3x and its current price is near the low end of its historical range; otherwise, NVST's stronger operating profile suggests EVH deserves a discount.
EVH trades at 0.3x P/S versus NVST at 1.7x, while the valuation model implies $27.79 per share versus the current $5.71, a 386.6% upside gap. However, that apparent mispricing is offset by EVH's sharply negative fundamentals, so the gap looks more like a quality discount than a clear valuation anomaly.
Supporting Metrics
